Medicine reading guide
Trastuzumab (Herceptin)
Intravenous Herceptin alone for HER2-positive metastatic breast cancer after chemotherapy. Educational draft. Independent clinical review pending. Not personal medical advice.
How it works
Some breast cancer cells have unusually high levels of a protein called HER2 on their surface. Trastuzumab attaches to HER2. Lab studies show it can slow the growth of cells with high HER2 levels and help immune cells target them. HER2 testing helps the care team decide whether this treatment fits the cancer.
Herceptin prescribing information · §§1.2, 2.2 and 12.1
Audience explanation sources
Editorial source review completed November 11, 2026. Independent clinical review pending. Audience versions explain the same scoped medicine; they are not separate treatment plans.
Educational draft. Independent clinical review pending.
Written explanation
Adults receiving single-agent intravenous Herceptin for HER2-overexpressing metastatic breast cancer after at least one chemotherapy regimen for metastatic disease. Excludes other settings, biosimilar-specific guidance, subcutaneous products and antibody-drug conjugates.
Existing authored material. Source-check record: 2026-10-12. Independent clinical review pending.
Target identified: trastuzumab binds the outside portion of the HER2 receptor. Treatment selection requires an appropriate HER2 test.
Tumor effects: laboratory studies show inhibited growth and antibody-dependent immune killing of HER2-overexpressing cells. This does not predict an individual response.
Which use does this guide cover?
This guide covers Herceptin given alone by infusion for breast cancer with extra HER2 that has spread, after prior chemotherapy for the cancer that has spread.
How does it work?
HER2 is a receiver on the surface of some cancer cells that helps carry growth signals. Trastuzumab attaches to HER2. Laboratory studies show that it can slow the growth of cells with extra HER2 and help immune cells attack them.
Why is a HER2 test needed?
An FDA-authorized companion diagnostic identifies tumors appropriate for Herceptin treatment.
Is it the same as a trastuzumab conjugate?
No. Do not substitute it for ado-trastuzumab emtansine or fam-trastuzumab deruxtecan.
How is it given?
A clinician administers it slowly into a vein in a medical facility.
What side effects might occur?
Nausea, diarrhea or headache may occur; tell the care team about persistent symptoms.
Why check my heart?
Serious heart problems can occur. Heart-function testing is needed before and during therapy.
When should I seek help?
Contact your team immediately for new breathlessness, swelling, rapid weight gain or a racing heartbeat. Severe breathing difficulty needs emergency care.
What should I report during infusion?
Tell staff immediately about chills, fever, throat tightness, rash or difficulty breathing.
Which cancer treatments raise concern?
Anthracyclines increase concern for heart toxicity, including after Herceptin stops. Your oncology team must coordinate treatment.
What about pregnancy?
Herceptin can harm a fetus. If you can become pregnant, use effective contraception during treatment and for seven months after the last dose. Contact your oncology team immediately if you think you may be pregnant.